Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Gut|June 4, 2025
Differential HCC risk among HBV indeterminate types at baseline and by phase transitionRui Huang, Huy N Trinh, Satoshi Yasuda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular CarcinomaDaniel Q Huang, Joseph K Hoang, Rubayet Kamal, et al.
Hepatology International|December 5, 2020
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohortYasuhito Tanaka, Eiichi Ogawa, Chung-Feng Huang, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
The American Journal of Gastroenterology|October 22, 2019
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis BYao-Chun Hsu, Grace Lai-Hung Wong, Chien-Hung Chen, et al.
Journal of Gastroenterology and Hepatology|March 13, 2024
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational studyTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
Pageof 13